Recent successful trials with monoclonal therapeutic antibodies targeting amyloid-beta have not only shown improvements in markers of Alzheimer’s disease (AD) pathology but also demonstrated potential in modifying the course of AD-related cognitive decline. While this treatment holds significant promise, it raises new questions, some with direct clinical implications like the drug bioavailability and the origin of Amyloid-Related Imaging Abnormalities (ARIA), while others are more theoretical, such as isolating the molecular determinants of antibody-antigen interaction and understanding the mechanism for amyloid beta plaque removal. Addressing these questions could significantly enhance the safety and efficiency of therapeutic antibodies against AD.

▼Seminar poster